The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial Results

Tuesday, February 05, 2013

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2012 Financial Results07:35 EST Tuesday, February 05, 2013 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Monday, February 25, 2013. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's financial results as of December 31, 2012, key corporate objectives and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on February 25, 2013 prior to the conference call. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com. The call can be accessed by dialing 866-831-6272 (domestic) or 617-213-8859 (international) five minutes prior to the start time and providing the pass code 59632303. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's first medicine, Iclusig™, is approved in the U.S. for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Additional clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113, another molecularly targeted medicine, in certain forms of lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm). ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams, 617-621-2208Kendra.adams@ariad.comorFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com